Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 388
Filtrar
Mais filtros










Filtros aplicados

Base de dados
Intervalo de ano de publicação
1.
Rev. patol. respir ; 23(supl.1): S1-S4, feb. 2020. tab
Artigo em Espanhol | IBECS | ID: ibc-188028

RESUMO

Las guías de práctica clínica (GPC) aparecieron con el fin de homogenizar el diagnóstico y tratamiento del asma; inicialmente como un consenso de expertos, y posteriormente incluyendo para sus afirmaciones y recomendaciones técnicas de medicina basada en la evidencia, e incorporar en sus actualizaciones frecuentes, los cambios en el conocimiento fisiopatológico y en el manejo de la enfermedad. En el 2019 se han realizado actualizaciones de las tres principales GPC incluyendo el tratamiento del paciente con asma grave no controlada, el uso de fármacos biológicos y otros procedimientos


The clinical practice guidelines (CPG) appeared with the intention to homogenize the asthma diagnosis and treatment, initially as an expert consensus, and afterwards including evidence based medicine data for its affirmations and technical recommendations incorporating advances in knowledge and management of the disease in their frequent updates. In 2019 the 3 principal CPG, have updates including the management of non-controlled severe asthma patients, biological treatments use and other procedures


Assuntos
Humanos , Asma/terapia , Guias de Prática Clínica como Assunto , Consenso , Recidiva , Produtos Biológicos/uso terapêutico , Glucocorticoides/administração & dosagem , Anticorpos Monoclonais/uso terapêutico , Imunoglobulina E/uso terapêutico , Interleucina-5/uso terapêutico , Interleucina-4/uso terapêutico , Azitromicina/uso terapêutico , Termoplastia Brônquica/métodos
2.
Allergol. immunopatol ; 48(1): 26-33, ene.-feb. 2020. ilus, graf
Artigo em Inglês | IBECS | ID: ibc-186588

RESUMO

Introduction and Objectives: The production and consumption of oysters is increasing annually because it can provide essential nutrients and benefit for human health, leading to frequent occurrence of severe allergic reactions observed in sensitized individuals. The aim of the present study was to investigate the effects of acid and protease treatment on the conformation and IgE-binding capacity of recombinant Crassostrea gigas tropomyosin (Cra g 1). Results: Under acidic conditions, Cra g 1 did not undergo degradation, however, the changes obvious in the intensity of CD signal and ANS-binding fluorescence were observed, which was associated with a decrease in antibody reactivity. In simulated gastrointestinal fluid (SGF) and simulated intestinal fluid (SIF) digestion system, acid-treated Cra g 1 was relatively resistant to digestion, but the degradative patterns were very different. Moreover, owing to alterations of secondary structure and hydrophobic surface of the protein during digestive processing, antigenicity of acid-induced Cra g 1 reduced in SGF while it increased significantly in SIF. Conclusion: To our knowledge, this is the first study reporting that antigenicity of acid-treated oyster tropomyosin increased after SIF digestion. These results revealed that treatment with acid and pepsin, rather than trypsin, was an effective way of reducing IgE-binding capacity of tropomyosin from oyster


No disponible


Assuntos
Humanos , Imunoglobulina E/imunologia , Técnicas In Vitro/métodos , Alérgenos/química , Tropomiosina/química , Hipersensibilidade Alimentar/imunologia , Digestão , Alérgenos/imunologia , Tropomiosina/imunologia , Ostreidae/imunologia , Sistema Digestório/imunologia , Eletroforese/métodos , Análise Espectral/métodos , Ensaio de Imunoadsorção Enzimática
3.
Allergol. immunopatol ; 48(1): 67-72, ene.-feb. 2020. tab, graf
Artigo em Inglês | IBECS | ID: ibc-186594

RESUMO

Background: There is little understanding of the mechanisms by which food allergy (FA) develops into persistent disease, or by which symptoms it regresses. Food allergy is a major health problem in developed countries, where the prevalence reaches up to 6% in children and 3% in the adult population. Objective: Children with food allergy remission (FAR) and those without FAR below five years of age, were compared 7-10 years with respect to clinical data and expression of glycoprotein A repetitions predominant (GARP) on peripheral blood mononuclear cells. Methods: Forty children with FAR and 40 children without FAR at age 7-10, in whom FA was previously diagnosed at age below five years were evaluated. In this prospective study, demographic and clinical data were taken, patients were classified as atopic based on history and serum specific IgE (sIgE) for a specific allergen. Blood samples were obtained from all patients to assess expression of GARP. Results: We observed higher expression of GARP in children with FAR compared to children without FA (p = 0.005); optimal cut-off for GARP prediction of the remission was 20.1%. Children with FAR and food-specific IgE in serum had higher expression of GARP compared to children with low food specific IgE (< 0.35 kU/L). Keeping pets at home decreased, and presence of allergic rhinitis increased ORs for high expression of GARP (hGARP) in our patients. Conclusion: hGARP (>20.1%) is related with FAR in school children. Allergic rhinitis, and pets at home modify this effect of GARP. Children with allergic rhinitis have less chance of developing remission despite maintaining immune tolerance (hGARP); quite the opposite case with pets at home


No disponible


Assuntos
Humanos , Criança , Hipersensibilidade Alimentar/diagnóstico , Hipersensibilidade Imediata/imunologia , Imunoglobulina E/sangue , Fatores de Transcrição , Glicoproteínas/imunologia , Hipersensibilidade Alimentar/imunologia , Imunoglobulina E/imunologia , Leucócitos Mononucleares/imunologia , Rinite Alérgica , Hipersensibilidade Alimentar/sangue , Estudos Prospectivos , Modelos Logísticos , Glicoproteínas/metabolismo
4.
Allergol. immunopatol ; 48(1): 84-89, ene.-feb. 2020. tab, graf
Artigo em Inglês | IBECS | ID: ibc-186597

RESUMO

Background and objectives: Vitamin D status may be related to allergen sensitizations, but the evidence is inconsistent. The objective of this study was to assess whether serum 25-hydroxyvitamin D (25(OH)D) levels were associated with allergic sensitizations in early childhood. Methods: Data were collected from 2642 children who visited the Guangdong Women and Children's Hospital from January 2016 to May 2017 for routine health check-ups. Serum 25(OH)D levels were tested by electrochemiluminescence immunoassay. Allergic sensitizations including food and inhalant allergens were tested for specific IgE antibodies at one year (12 months 0 days through 12 months 30 days) and two years (24 months 0 days through 24 months 30 days) of age. Results: The mean level of serum 25(OH)D was 86.47 ± 27.55 nmol/L, with a high prevalence of vitamin D insufficiency (< 75 nmol/L) in children aged 0-2 years (36.8%). Lower 25(OH)D levels with serum total IgE of more than 200IU/mL (81.54 ± 25.53 nmol/L) compared with less than 100 IU/mL (87.92 ± 28.05 nmol/L). The common sensitization to allergens in children aged one and two years were milk (44.2%), cat epithelium (26.4%), egg (13.1%), dog epithelium (12.7%) and Dermatophagoides farinae (6.7%). After multivariate adjustment, data in 25(OH)D treated as a continuous variable or categories, no consistent associations were found between 25(OH)D levels and allergen-specific IgEs. Conclusions: Serum 25(OH)D level showed an inverse relationship with total IgE level in early childhood. However, there is lack of evidence to support associations between low 25(OH)D levels and allergic sensitization to various allergens


No disponible


Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Vitamina D/análogos & derivados , Imunização/métodos , Imunoglobulina E/sangue , Hipersensibilidade/diagnóstico , Técnicas Imunoenzimáticas , Imunoglobulina E/imunologia , China
5.
Allergol. immunopatol ; 48(1): 95-104, ene.-feb. 2020. tab, graf
Artigo em Inglês | IBECS | ID: ibc-186599

RESUMO

Introduction: Food allergy is considered a public health problem for children. The modulation of the intestinal microbiota seems a promising strategy for the control of allergic reactions. Objective: To describe the effects of different forms of probiotics in pediatric food hypersensitivity treatment. Data source: We conducted a systematic review based on clinical trials published in the PubMed and Web of Science databases. The searches were carried out using the MeSH terms "Food Hypersensitivity", "Probiotics," "Lactobacillus", and "Bifidobacterium". Data synthesis: The final selection resulted in 18 clinical trials, which were predominantly samples of infants and pre-school children. The most-often used strain, either alone or in combination, was Lactobacillus rhamnosus GG; a placebo was mainly used in the control group. As for the vehicle, the most common forms were capsules and infant formulas, and the period of intervention ranged from four weeks to 24 months, with weekly or monthly visits to measure the outcomes. In these 18 trials, 46 analyses were performed with 27 different types of outcomes to evaluate the effects of probiotics (12 laboratory and 15 clinical). Twenty-seven of these analyses demonstrated the benefits of using these microorganisms. The SCORAD (atopic dermatitis index) and IgE levels and cytokines were the outcomes mostly evaluated. Conclusion: The use of probiotics is beneficial in promoting immunomodulation and reducing clinical symptoms. However, more methodologically based research is needed to clarify the effect from each type, dose, and time of using them for the establishment of definitive care protocols


No disponible


Assuntos
Humanos , Criança , Adolescente , Hipersensibilidade Alimentar/terapia , Probióticos/uso terapêutico , Microbioma Gastrointestinal/imunologia , Imunomodulação , Lactobacillus/imunologia , Dermatite Atópica/imunologia , Imunoglobulina E
6.
Farm. hosp ; 43(6): 187-193, nov.-dic. 2019. tab
Artigo em Espanhol | IBECS | ID: ibc-187480

RESUMO

Objetivo: Mepolizumab está indicado como tratamiento adicional del asma eosinofílica refractaria grave. Las diferencias observadas en subgrupos poblacionales según recuento eosinofílico plasmático, existencia de pacientes con altos niveles de inmunoglobulina E candidatos a omalizumab y mepolizumab, e impacto económico de mepolizumab obligan a realizar estudios económicos para tomar decisiones clínicas eficientes. El objetivo fue realizar un análisis de coste/eficacia e impacto presupuestario de mepolizumab. Método: Se realizó la comparación de costes e impacto presupuestario del uso de mepolizumab desde la perspectiva del Sistema Nacional de Salud. Las alternativas valoradas fueron corticosteroides sistémicos inhalados + agonista ß2 de larga duración y/o corticosteroides sistémicos orales en pacientes con asma alérgica grave no mediada por inmunoglobulina E, y este tratamiento junto a omalizumab en pacientes con asma eosinofílica alérgica mediada por inmunoglobulina E. La eficacia se evaluó mediante exacerbaciones clínicamente relevantes evitadas. Se valoraron los costes directos asociados a exacerbación. Resultados: El coste incremental medio de mepolizumab respecto a omalizumab es de 797 euros por paciente y año. Considerando precio alternativo con descuento de omalizumab, incluir mepolizumab para pacientes con asma eosinofílica alérgica y mediada por inmunoglobulina E supondría incrementar el gasto público de 2,3 a 4,6 millones de euros. Teniendo en cuenta el precio notificado de omalizumab, la introducción gradual de mepolizumab en el Sistema Nacional de Salud supondría ahorrar 3,6 millones de euros en tres años. Para pacientes con asma grave no mediada por inmunoglobulina E, el coste/exacerbación evitada al añadir mepolizumab es de 15.085 euros, con un impacto presupuestario en tres años de 578,4 millones de euros, asumiendo una penetración progresiva de mepolizumab en el mercado. En los pacientes con ≥ 500 eosinófilos/µl, este coste disminuye a 7.767 euros por exacerbación evitada, con un impacto presupuestario de 183,2 millones de euros en tres años con penetración progresiva de mepolizumab. Conclusiones: La comparación de costes entre mepolizumab y omalizumab en pacientes con asma eosinofílica mediada por inmunoglobulina E señala como razonable utilizar el fármaco de menor coste, promoviendo competencia de precios. Asimismo, priorizar su uso en pacientes con asma eosinofílica refractaria grave no mediada por inmunoglobulina E y niveles plasmáticos ≥ 500 eosinófilos/µl permitiría mejorar la eficiencia y disminuir el impacto presupuestario


Objective: Mepolizumab is indicated as additional treatment of severe refractory eosinophilic asthma. Differences in subgroups according to plasmatic eosinophil count, existence of patients with high levels of immunoglobulin E candidates for omalizumab and mepolizumab, and budget impact of mepolizumab require economic studies for efficient clinical decisions. The objective was to perform a cost-efficacy and budget impact analysis of mepolizumab. Method: An analysis of comparison of costs and budgetary impact of use of mepolizumab has been performed from National Health System perspective. Evaluated alternatives were inhaled systemic corticosteroids + long-acting ß2-agonist and/or oral systemic corticosteroids in patients with severe allergic asthma not mediated by immunoglobulin E, and the same treatment associated with omalizumab in patients with immunoglobulin E-mediated allergic eosinophilic asthma. Efficacy was assessed by clinically relevant exacerbations avoided. Direct costs associated with exacerbation were assessed Results: An average incremental cost of 797 euros/patient-year was estimated. Considering alternative price with discount for omalizumab, including mepolizumab for patients with immunoglobulin E-mediated allergic eosinophilic asthma would increase public spending from 2.3 to 4.6 million euros. According reported price for omalizumab, gradual introduction of mepolizumab into the National Health System would save 3.6 million euros in three years. For patients with immunoglobulin E-not mediated severe asthma, adding mepolizumab presented a cost/exacerbation avoided of 15,085 euros and a budgetary impact for three years of 578.4 million euros according a progressive penetration of mepolizumab in market. In patients with ≥ 500 eosinophils/μL, cost/exacerbation avoided is reduced to 7,767 euros and the budgetary impact is 183.2 million euros in three years according progressive penetration of mepolizumab. Conclusions: With analysis of cost comparison of mepolizumab vs. omalizumab in patients with eosinophilic immunoglobulin E-mediated asthma, it would be reasonable to prioritize the drug more economic to promote price competition. According this pharmacoeconomic study, prioritizing mepolizumab in patients with immunoglobulin E-not mediated severe refractory eosinophilic asthma and higher plasmatic eosinophil count (≥ 500 eosinophils/μL) would improve efficiency and decrease budgetary impact


Assuntos
Humanos , Antiasmáticos/economia , Antiasmáticos/uso terapêutico , Anticorpos Monoclonais/economia , Anticorpos Monoclonais/uso terapêutico , Asma/tratamento farmacológico , Asma/economia , Asma/imunologia , Custos e Análise de Custo , Custos de Medicamentos , Resistência a Medicamentos , Eosinófilos , Imunoglobulina E/imunologia , Espanha
7.
Allergol. immunopatol ; 47(6): 579-584, nov.-dic. 2019. tab, graf
Artigo em Inglês | IBECS | ID: ibc-186551

RESUMO

Background: In Portugal, the pollen types most implicated in respiratory allergy are grasses, olive and parietaria. The knowledge of sensitizations to molecular allergens in children and adults can contribute to better diagnosis and treatment of this pathology. Methods: ImmunoCAP singleplex technology was used for molecular allergens and Phadia 250(R) automatic equipment. g205 (Phl p1); g215 (Phl p5b); g210 (Phl p7); and g212 (Phl p12) allergen determinations were made in 45 patients with positive grass sensitization tests. Results: The majority of patients are sensitized to Phl p1 (91%) and Phl p1+/Phl p5-/Phl p7-/Phl p12- was the most dominant profile (40%). In the adult group, the IgE averages for Phl p1 were approximately 10.46, while they were 8.43 for Phl p5, 0.69 for Phl p7, and 0.06 for Phl p12. In the child group, these values were higher: 22.49, 20.23, 3.89, and 0.35, respectively. For allergens Phl p1, Phl p5, and Phl p7, these differences between the child and adult population were not statistically significant (p = 0.754, p = 0.806 and p = 0.102, respectively), but for Phl p12, a statistically significant difference (p = 0.018) was observed. Conclusions: IgE antibodies Phl p1 is the most important allergic marker and sensitivities caused by Phl p12 give rise to higher IgE values in children


No disponible


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Alérgenos/administração & dosagem , Alérgenos/imunologia , Imunização/métodos , Pólen/classificação , Técnicas de Imunoadsorção , Hipersensibilidade/diagnóstico , Imunoglobulina E/análise , Portugal , Hipersensibilidade/imunologia , Pólen/imunologia , Imunoterapia
8.
Allergol. immunopatol ; 47(5): 449-456, sept.-oct. 2019. tab, graf
Artigo em Inglês | IBECS | ID: ibc-186519

RESUMO

Background: Limited studies conducted on children <2 years old and/or involving a skin prick test (SPT) for fresh milk (FM) have examined the predictive value of allergometric tests for outgrowth of cow's milk allergy (CMA). We investigated the optimal decision points for outgrowth (ODPfo) with SPT for commercial cow's milk extract (CE) and FM and specific immunoglobulin E (sIgE) levels for milk proteins to predict outgrowing allergy in children < 2 years old. Methods: SPTs for CE and FM, tests for sIgEs (cow's milk, casein, alfa-lactoalbumin, Beta-lactoglobulin) and oral food challenges (OFC) were performed in children referred for evaluation of suspected CMA, and 15 months after diagnosis. Results: Fifty-one children (median age, 7.5 months; range, 2-23 months) were enrolled. Five had a history of anaphylaxis and 26 of 48 children with a positive initial challenge underwent milk elimination. The last OFC was performed in 28 children of whom 13 reacted to milk. The initial SPT responses to CE and FM and milk sIgE levels of the patients with persistent CMA were higher at diagnosis, with ODPfo of 7 mm, 9 mm, and 10.5 kU/L, respectively; these values remained higher with ODPfo of 4 mm, 11 mm, and 10.5 kU/L at the last OFC. Conclusion: Higher initial SPTs for FM and CE and higher initial sIgE levels for cow's milk proteins are associated with a reduced likelihood of outgrowth. Initial milk sIgE level < 10.5 kU/L and initial SPT for fresh milk < 9mm are related to the acquisition of tolerance in the follow-up period


No disponible


Assuntos
Humanos , Animais , Masculino , Feminino , Lactente , Gatos , Alérgenos/imunologia , Testes Diagnósticos de Rotina/métodos , Imunoglobulina E/metabolismo , Hipersensibilidade a Leite/diagnóstico , Proteínas do Leite/imunologia , Tomada de Decisão Clínica , Tolerância Imunológica , Prognóstico , Testes Cutâneos
10.
Allergol. immunopatol ; 47(4): 322-327, jul.-ago. 2019. tab
Artigo em Inglês | IBECS | ID: ibc-186502

RESUMO

Background: Children with IgE-mediated cow's milk allergy (IgE-CMA) with gastrointestinal symptoms tolerate yogurt at 100%. Yogurt tolerance in children with IgE-CMA with urticaria and anaphylaxis was 7%. Methods: We enrolled children with IgE-CMA with cutaneous, respiratory, gastrointestinal and anaphylactic symptoms. All performed prick by prick (PbP) and oral food challenge (OFC) with yogurt. Some children performed also an OFC with CM mixed with wheat flour and baked, baked liquid CM, parmesan. Results: 34 children were enrolled, 31/34 (91%) with systemic adverse reaction after ingestion of CM (systemic CMA), 3/34 (9%) with isolated contact urticaria (ICU CMA). PbP with yogurt was negative only in one patient. OFC with yogurt was passed (that is, the OFC was negative) by 20/31 (64%) of the children with systemic CMA. 10/11 (91%) of the patients who failed OFC (that is, the OFC was positive) with yogurt were positive to SPT with casein vs. 8/20 (40%) of the patients who passed it (p = 0.018). None of the 19 children who passed OFC with yogurt failed all OFC with processed CM forms other than yogurt that tested vs. 4/8 among those who failed OFC with yogurt (p = 0.006). The rub test with yogurt was negative in 1/3 (33%) of the patients with ICU CMA. Conclusions: The results of our study are placed alongside others already present in the literature and concerning other methods of processing CM proteins and help to reduce the dietary restrictions of the majority of children with systemic IgE-CMA


No disponible


Assuntos
Humanos , Animais , Masculino , Feminino , Lactente , Pré-Escolar , Gatos , Imunoglobulina E/metabolismo , Hipersensibilidade a Leite/imunologia , Iogurte , Administração Oral , Alérgenos/imunologia , Caseínas/imunologia , Tolerância Imunológica , Testes Cutâneos
11.
Allergol. immunopatol ; 47(4): 336-341, jul.-ago. 2019. tab, graf
Artigo em Inglês | IBECS | ID: ibc-186504

RESUMO

Introduction and objectives: Omalizumab is present in international guidelines for the control of severe asthma, but data on the long-term effects in children are limited. Our objective was to perform a 'eal-life' long-term trial of omalizumab in children with allergic asthma. Materials and methods: An observational single center 'real-life' study was performed. Data for treatment, lung function, side effect, asthma exacerbations and hospitalizations were recorded at six months and annually. Results: Forty-eight patients <18 years of age were enrolled. Median treatment period was 2.9 (0.5-6). Fluticasone dose for the maintenance treatment decreases significantly at six months (452mcg/day to 329.89 mcg/day, respectively). This difference was maintained throughout the follow-up. Nobody used oral corticosteroid after six months. The rate of hospital admissions and visits to the emergency department for asthma exacerbations decreased significantly in the third years and fourth years follow-up, respectively. There was an improvement in lung function. Mean values of FEV1 and FEF25-75% before treatment were 79.88 and 62.94, respectively; after six months of treatment a statistically significant change was seen with a mean FEV1 of 92.29 and FEF25-75% of 76.31 (p = 0.0001). Lung function values were above normal throughout the six years of treatment. No side effects were reported. Conclusions: Overall in 'real life' omalizumab in children reduces asthma exacerbations and hospitalizations, improves lung function, and decreases the maintenance therapy. It is shown to be safe for up to six years of treatment in children


No disponible


Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Omalizumab/uso terapêutico , Progressão da Doença , Seguimentos , Hospitalização , Imunoglobulina E/imunologia , Imunoglobulina E/metabolismo , Guias de Prática Clínica como Assunto , Índice de Gravidade de Doença , Espirometria , Resultado do Tratamento
12.
Allergol. immunopatol ; 47(4): 357-364, jul.-ago. 2019. tab, graf
Artigo em Inglês | IBECS | ID: ibc-186507

RESUMO

Introduction: Amaranthus retroflexus (Redroot Pigweed) is one of the main sources of allergenic pollens in temperate areas. Polcalcin is a well-known panallergen involved in cross-reactivity between different plants. The aim of this study was the molecular cloning and expression of polcalcin, as well as evaluating its IgE-reactivity with A. retroflexus sensitive patients' sera. Methods: Allergenic extract was prepared from A. retroflexus pollen and the IgE-reactivity profile was determined by ELISA and immunoblotting using sera from twenty A. retroflexus sensitive patients. Polcalcin-coding sequence was amplified by conventional PCR method and the product was inserted into pET-21b(+) vector. The recombinant protein was expressed in E. coli BL21 and purified by metal affinity chromatography. The IgE-binding capability of the recombinant protein was analyzed by ELISA and immunoblotting assays, and compared with crude extract. Results: Of 20 skin prick test positive patients, 17 patients were positive in IgE-specific ELISA. Western blotting confirmed that approximately 53% of ELISA positive patients reacted with 10kDa protein in crude extract. The A. retroflexus polcalcin gene, encoding to 80 amino acid residues was cloned and expressed as a soluble protein and designated as Ama r 3. The recombinant polcalcin showed rather identical IgE-reactivity in ELISA and western blotting with 10 kDa protein in crude extract. These results were confirmed by inhibition methods, too. Conclusion: The recombinant form of A. retroflexus polcalcin (Ama r 3) could be easily produced in E. coli in a soluble form and shows rather similar IgE-reactivity with its natural counterpart


No disponible


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto Jovem , Adulto , Alérgenos/imunologia , Amaranthus/imunologia , Antígenos de Plantas/imunologia , Proteínas de Ligação ao Cálcio/imunologia , Pólen/imunologia , Rinite Alérgica Sazonal/imunologia , Testes Cutâneos , Alérgenos/isolamento & purificação , Antígenos de Plantas/isolamento & purificação , Proteínas de Ligação ao Cálcio/isolamento & purificação , Clonagem Molecular , Reações Cruzadas , Escherichia coli/genética , Expressão Gênica , Imunoglobulina E/metabolismo , Extratos Vegetais , Proteínas Recombinantes/isolamento & purificação
13.
Allergol. immunopatol ; 47(4): 365-371, jul.-ago. 2019. tab
Artigo em Inglês | IBECS | ID: ibc-186508

RESUMO

Introduction and objectives: The amounts of Akkermansia muciniphila and Faecalibacterium prausnitzii in gut microbiota are reduced in patients with allergic diseases compared to healthy controls. We aimed to quantify levels of A. muciniphila and F. prausnitzii amounts using real-time quantitative PCR (qPCR) in the gut microbiota of children with allergic asthma and in healthy controls. Materials and methods: In total, 92 children between the ages of three and eight who were diagnosed with asthma and 88 healthy children were included in the study and bacterial DNA was isolated from the stool samples using the stool DNA isolation Kit. qPCR assays were studied with the microbial DNA qPCR Kit for A. muciniphila and microbial DNA qPCR Kit for F. prausnitzii. Results: Both bacterial species showed a reduction in the patient group compared to healthy controls. A. muciniphila and F. prausnitzii were found to be 5.45 ± 0.004, 6.74 ± 0.01 and 5.71 ± 0.002, 7.28 ± 0.009 in the stool samples of the asthma and healthy control groups, respectively. Conclusions: F. prausnitzii and A. muciniphila may have induced anti-inflammatory cytokine IL-10 and prevented the secretion of pro-inflammatory cytokines like IL-12. These findings suggest that A. muciniphila and F. prausnitzii may suppress inflammation through its secreted metabolites


No disponible


Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Criança , Asma/microbiologia , DNA Bacteriano/genética , Eosinófilos/imunologia , Faecalibacterium prausnitzii/fisiologia , Fezes/microbiologia , Microbioma Gastrointestinal/genética , Verrucomicrobia/fisiologia , Imunoglobulina E/sangue , Probióticos , Reação em Cadeia da Polimerase em Tempo Real
14.
Allergol. immunopatol ; 47(4): 401-408, jul.-ago. 2019. graf, ilus
Artigo em Inglês | IBECS | ID: ibc-186512

RESUMO

The variety of foods and methods of preparation are part of the cultural identity of each population, and thus the main foods that cause symptoms vary among different regions. Due to their increasing frequency, Adverse Reactions to Food (AFR) have been the subject of extensive study, especially in North America and Europe but few studies have been conducted in other areas, especially in populations located in the tropics and subtropics. In this article, we review available information on the epidemiology of food sensitization and food allergies in tropical regions and explore the different epidemiological data considering the major food involved, the underlying immune mechanism and clinical symptoms partners. In addition, we identify the possible limitations and questions that arise from studies conducted in tropical countries, which helps to generate objectives for future research


No disponible


Assuntos
Humanos , Dermatite Atópica/epidemiologia , Hipersensibilidade Alimentar/epidemiologia , Clima Tropical , Alérgenos/imunologia , África/epidemiologia , Ásia/epidemiologia , Imunização , Imunoglobulina E/metabolismo , América Latina/epidemiologia , Prevalência
15.
Allergol. immunopatol ; 47(3): 214-220, mayo-jun. 2019. graf, tab, ilus
Artigo em Inglês | IBECS | ID: ibc-186480

RESUMO

Background: Allergy to cow's milk proteins has often been associated with dysfunction of the intestinal mucosa caused by chronic inflammation in infants. This study evaluated the protective effect of taurine on intestinal damage induced by beta-lactoglobulin (Beta-Lg) in Balb/c mice used as an animal model of allergy to cow's milk proteins. Methods: Balb/c mice were treated with taurine administered orally by gavage (3 mmol/kg/day) or intraperitoneally (100 mg/kg/day) for two weeks, then sensitized intraperitoneally with Beta-Lg. The electrophysiological parameters: active ion transport of chloride (Short-circuit current: Isc) and the passive ion permeability (Conductance: G) were measured ex vivo in Ussing chamber by intestine challenge with Beta-Lg. Histological study was used to assess gut inflammation. Serum levels of TNF-α and IL-6 were measured. Serum IgG and IgE anti-Beta-Lg were determined by ELISA. Results: Compared with sensitized mice, Beta-Lg challenge of intestinal epithelium of taurine-pre-treated mice in Ussing chamber did not influence the intensity of Isc, nor produce any changes in the G, reflecting a reduction in the secretory response and epithelial permeability. Histological and morphometric analysis showed that taurine reduced the intestinal damage and limited intestine retraction caused by Beta-Lg sensitization. No statistically significant difference in the serum levels of TNF-α or IL-6 was found after oral or intraperitoneal administration of taurine. Treatment with taurine significantly decreased the IgG (p < 0.001) and IgE anti Beta-Lg levels (p < 0.05). Conclusions: These results have for the first time provided evidence that pre-treatment with taurine appears to prevent intestinal damage induced by Beta-Lg


No disponible


Assuntos
Animais , Feminino , Camundongos , Hipersensibilidade Alimentar/tratamento farmacológico , Inflamação/tratamento farmacológico , Mucosa Intestinal/efeitos dos fármacos , Taurina/uso terapêutico , Modelos Animais de Doenças , Alérgenos/imunologia , Imunidade Humoral/efeitos dos fármacos , Imunização , Imunoglobulina E/sangue , Imunoglobulina G/sangue , Interleucina-6/sangue , Mucosa Intestinal/imunologia , Lactoglobulinas/imunologia , Camundongos Endogâmicos BALB C , Fator de Necrose Tumoral alfa/sangue
16.
Allergol. immunopatol ; 47(3): 234-240, mayo-jun. 2019. graf, tab
Artigo em Inglês | IBECS | ID: ibc-186483

RESUMO

Introduction and objectives: Allergic rhinitis (AR) is a classic Th2-mediated disease, with important contributions to the pathology of interleukins 4, 5, and 13. The co-stimulatory molecule of OX40 and its ligand interaction participate in the immune response by regulation of Th1/Th2 cells balance. Considering the paucity of information on the relation between OX40 ligand (OX40L) and AR, this study aimed to examine its expression on B lymphocytes. Patients and methods: This case-control study consisted of 20 AR patients and 20 healthy subjects. The serum level of total immunoglobulin E (IgE) was measured using the electro-chemiluminescence (ECL) technology. The percentage of B-lymphocytes expressing OX40L was assessed by flow cytometry. The amounts of IL-4 in CD4+ T cells culture supernatant was also measured by the enzyme-linked immunosorbent assay (ELISA). Results: OX40L expression on B lymphocytes of patients was significantly higher than the control group (44.32 ± 19.21% vs. 2.79 ± 2.48% respectively, p < 0.001). In AR patients, OX40L expression correlated positively with the levels of serum total IgE and IL-4 produced by CD4+ T lymphocytes (p < 0.01 - p < 0.05) respectively. Conclusions: Collectively, the findings of this work suggest that there is a relationship between the OX40L expression level on B lymphocytes and allergic markers such as IgE and IL-4 in patients with allergic rhinitis


No disponible


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Linfócitos B/imunologia , Biomarcadores/sangue , Imunoglobulina E/sangue , Interleucina-4/sangue , Ligante OX40/metabolismo , Rinite Alérgica/imunologia , Células Th2/imunologia , Antígenos CD4/metabolismo , Estudos de Casos e Controles , Regulação para Cima , Células Cultivadas
17.
Allergol. immunopatol ; 47(3): 272-276, mayo-jun. 2019. ilus
Artigo em Inglês | IBECS | ID: ibc-186489

RESUMO

Background: Murine models have been widely used in the study of allergy as sensitized mice can produce IgE and/or IgG1in response after the injection of an antigen/adjuvant combination. Ailanthus altissima pollen (AAP) has been recently reported as an emerging aeroallergen in Iran. So far, several AAP candidate allergens by the screening of allergen-specific IgE in the sera from AAP sensitized patients in Iran. Objective: The aim of the present study was to detect and compare the allergens eliciting an IgE response in a mouse model, and in human, using pollen extract of A. altissima and an immunoproteomics based approach. Methods: The pollen proteins were extracted in phosphate-buffered saline (PBS). Thirty male BALB/c mice were randomly divided into two groups of AP extract sensitized and sham that respectively received AAP PBS extract and a PBS control by intraperitoneal injections at regular intervals. The optimized AAP protein extracts were analyzed using 2D-gel electrophoresis and were subsequently confronted to pooled sera of sensitized mice. Results: Two-D gel electrophoresis of AAP extract allowed the separation of 125 protein spots distributed in a wide range of pI and molecular masses. Two-DE immunoblotting using pooled sera of sensitized mice led to the detection of 14 IgE reactive spots with molecular masses ranging from 12 to 40-42kDa. Conclusion: The results do not correlate with our previous analyses using human AAP-sensitized sera. These findings reflect some differences in the sIgE reactivity to allergenic proteins in animal models


No disponible


Assuntos
Humanos , Animais , Masculino , Camundongos , Ailanthus/imunologia , Alérgenos/metabolismo , Antígenos de Plantas/metabolismo , Soros Imunes/metabolismo , Pólen/metabolismo , Rinite Alérgica Sazonal/imunologia , Alérgenos/imunologia , Antígenos de Plantas/imunologia , Modelos Animais de Doenças , Imunoglobulina E/metabolismo , Camundongos Endogâmicos BALB C , Extratos Vegetais , Pólen/imunologia , Eletroforese em Gel Diferencial Bidimensional
18.
Allergol. immunopatol ; 47(3): 277-281, mayo-jun. 2019. tab
Artigo em Inglês | IBECS | ID: ibc-186490

RESUMO

Introduction and objectives: The reproducibility of the adverse reaction increases the suggestiveness of a history of food allergy. However, the positive predictive value (PPV) of multiple adverse reaction episodes for the diagnosis of IgE-mediated food allergy is not known. This evaluation was the objective of our study. Patients and methods: We retrospectively studied 180 children with a history of non-anaphylactic adverse reactions after the ingestion of a food. All children had the prick test positive for the offending food and performed the oral food challenge (OFC) within 12 months after the last adverse reaction episode (ARE). We have evaluated whether increasing the number of ARE increased the probability that the OFC would be positive (failed). Results: 93 patients (52%) presented one ARE, 49 (27%) presented two ARE, 24 (13%) presented three ARE, 14 (8%) patients presented ≥ four ARE. The OFC was positive in 94/180 (52%). The outcome of the OFC was found to be positively correlated with the number of ARE (OR = 1.56; 95% CI = 1.16-2.09; p = 0.003). A PPV = 100% was observed with a number of ARE ≥ five. Conclusions: The number of ARE is an important predictor of the diagnosis of food allergy, although less than we would have imagined. The number of ARE could be used to increase the predictability of the diagnostic tests currently in use, to define clinical prediction rules alternative to OFC and easy to use in clinical practice


No disponible


Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Pré-Escolar , Anafilaxia/diagnóstico , Hipersensibilidade Alimentar/diagnóstico , Anafilaxia/epidemiologia , Administração Oral , Alérgenos/imunologia , Alimentos , Hipersensibilidade Alimentar/epidemiologia , Imunização , Imunoglobulina E/metabolismo , Itália/epidemiologia , Valor Preditivo dos Testes , Prognóstico , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA